Popular Pharmaceuticals
Empagliflozin Diabetes & metabolic
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Glycenor | 25 mg | Tablet | BDT 50 | US$0.41 | 1 x 10: ৳ 500.00 |
| Glycenor | 10 mg | Tablet | BDT 25 | US$0.20 | 2 x 10: ৳ 500.00 |
Insulin Glargine Diabetes & metabolic
Originator: Lantus · Sanofi
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Insul Glargine | 100 IU/ml | SC Injection | — | — | — |
Linagliptin Diabetes & metabolic
Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Linajen | 5 mg | Tablet | BDT 20 | US$0.16 | 3 x 10: ৳ 600.00 |
Tofacitinib Immunology & rheumatology
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Jakloc / Jakloc XR | 5 mg tablet, 11 mg XR tablet | — | — | — | — |
| Jakloc | 5 mg | Tablet | BDT 48 | US$0.39 | 1 x 10: ৳ 480.00 |
| Jakloc XR | 11 mg | Tablet (Extended Release) | BDT 60 | US$0.49 | 1 x 10: ৳ 600.00 |
Vildagliptin Diabetes & metabolic
Originator: Galvus · Novartis
| Brand | Strength | Form | Unit price | ≈ USD | Pack |
|---|---|---|---|---|---|
| Galvid | 50 mg | Tablet | BDT 18 | US$0.15 | 3 x 10: ৳ 540.00 |
This page is an information resource for healthcare professionals, licensed importers and patients under medical care. It is not medical advice, not a prescription service, and not an offer to sell prescription medicines to the public.
Need a verified quotation?
Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.
We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.